<DOC>
	<DOCNO>NCT00089661</DOCNO>
	<brief_summary>The purpose trial evaluate AMG 162 treatment bone loss subject undergoing Aromatase Inhibitor Therapy Non-metastatic Breast Cancer .</brief_summary>
	<brief_title>AMG 162 Treatment Bone Loss Subjects Undergoing Aromatase Inhibitor Therapy Non-metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma breast Subjects early stage disease estrogen receptor positive complete treatment pathway ( surgery , chemotherapy , radiation , and/or hormone therapy ) currently initiate aromatase inhibitor therapy , expect stay aromatase inhibitor therapy duration 24month study All treatment pathway must complete ≥ 4 week prior study entry , acute toxic effect therapy must resolve ≤ Grade 1 National Cancer Institution ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) Female &gt; 18 year age ECOG Performance status 0 1 Lumbar spine , total hip femoral neck BMD equivalent tscore classification 1.0 2.5 Subject willing able provide sign consent studyspecific procedure Other criterion also apply .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Bone loss associate Aromatase Inhibitor therapy ( AIT ) non-metastatic BC</keyword>
	<keyword>osteopenia</keyword>
	<keyword>Low bone density</keyword>
</DOC>